Global Lung Cancer Drugs Market Growth Rate 2024, Forecast To 2033
16 Jan, 2024
The lung cancer drugs market has experienced rapid growth, increasing from $42.3 billion in 2023 to $47.72 billion in 2024, with a 12.8% CAGR. Historic growth is attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness, and education. The market is expected to continue its rapid growth, reaching $74.81 billion in 2028, with an 11.9% CAGR. Factors influencing growth in the forecast period include health insurance and reimbursement policies, healthcare infrastructure and access, and emerging markets. Major trends include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials, and research.
Global Lung Cancer Drugs Market Key Driver
The rising prevalence of lung cancer is a major driver for the lung cancer drugs market. The increase in lung cancer cases necessitates efficient drugs for speedy treatment, emphasizing the industry's need for a robust drug pipeline. According to the American Cancer Society, an estimated 238,340 new cases of lung cancer and 127,070 deaths were projected in 2023. This surge in lung cancer prevalence propels the growth of the lung cancer drugs market.
Get A Free Sample Of The Global Lung Cancer Drugs Market ReportGlobal Lung Cancer Drugs Market Segments
The lung cancer drugs market covered in this report is segmented –
1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals, Clinics, Other End-Users
By Geography: The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the lung cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Lung Cancer Drugs Industry Players
Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals plc, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC
Get The Full Global Lung Cancer Drugs Market Report
Lung Cancer Drugs Market Overview
Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Lung Cancer Drugs Global Market Report 2023 provides data on the global lung cancer drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The lung cancer drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.